Stouthard J M, Levi M, Hack C E, Veenhof C H, Romijn H A, Sauerwein H P, van der Poll T
Department of Internal Medicine, University of Amsterdam, The Netherlands.
Thromb Haemost. 1996 Nov;76(5):738-42.
The role of IL-6 as a mediator of haemostatic changes during severe inflammation is controversial. To assess the effect of IL-6 on haemostasis we conducted a controlled cross-over study in eight patients with metastatic renal cell cancer. In all subjects coagulation and fibrinolysis were monitored during and after a 4-h infusion of either 150 micrograms recombinant human (rh) IL-6, or during infusion of saline (control study). Mean maximum IL-6 concentrations were 1418.0 +/- 755.8 pg/ml. Compared to the control study, rhIL-6 induced activation of coagulation as reflected by a 190 +/- 55% increase in the plasma levels of thrombin-antithrombin III complexes (p < 0.001) and by a 24 +/- 11% increase in the plasma levels of in the prothrombin activation fragment F1 + 2 (p < 0.001). In contrast, fibrinolysis was not affected. We conclude that in severe inflammation IL-6 may contribute to the activation of coagulation, whereas other factors mediate changes in fibrinolysis.
白细胞介素-6（IL-6）在严重炎症期间作为止血变化介质的作用存在争议。为评估IL-6对止血的影响，我们对8例转移性肾细胞癌患者进行了一项对照交叉研究。在所有受试者中，于4小时输注150微克重组人（rh）IL-6期间及之后监测凝血和纤维蛋白溶解情况，或在输注生理盐水期间进行监测（对照研究）。平均最大IL-6浓度为1418.0±755.8皮克/毫升。与对照研究相比，rhIL-6诱导了凝血激活，表现为凝血酶 - 抗凝血酶III复合物血浆水平升高190±55%（p<0.001）以及凝血酶原激活片段F1 + 2血浆水平升高24±11%（p<0.001）。相比之下，纤维蛋白溶解未受影响。我们得出结论，在严重炎症中，IL-6可能促成凝血激活，而其他因素介导纤维蛋白溶解的变化。
